Analysts have been eager to weigh in on the Healthcare sector with new ratings on Athenex (ATNX), Intercept Pharma (ICPT) and Omeros (OMER).
Athenex (ATNX)
In a report issued on August 7, Kennen MacKay from RBC Capital reiterated a Buy rating on Athenex, with a price target of $31.00. The company’s shares closed last Monday at $11.90.
According to TipRanks.com, MacKay is a 5-star analyst with an average return of 11.7% and a 54.2% success rate. MacKay covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Aimmune Therapeutics, and Puma Biotechnology.
Athenex has an analyst consensus of Strong Buy, with a price target consensus of $28.00, which is a 151.3% upside from current levels. In a report issued on August 6, Needham also reiterated a Buy rating on the stock with a $30.00 price target.
See today’s analyst top recommended stocks >>
Intercept Pharma (ICPT)
In a report released today, Alan Carr from Needham assigned a Buy rating to Intercept Pharma, with a price target of $100.00. The company’s shares closed last Monday at $49.61, close to its 52-week low of $42.19.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 0.8% and a 41.5% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intercept Pharma with a $67.65 average price target, which is a 35.7% upside from current levels. In a report issued on July 30, Piper Sandler also initiated coverage with a Buy rating on the stock with a $82.00 price target.
Omeros (OMER)
In a report released today, Serge Belanger from Needham maintained a Hold rating on Omeros. The company’s shares closed last Monday at $21.09.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of 2.2% and a 40.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
Currently, the analyst consensus on Omeros is a Moderate Buy with an average price target of $25.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
